Opinion: A consultant wrote the playbook on drug pricing — then distanced himself from it
When Biogen announced the price for Aduhelm, its controversial Alzheimer’s drug, the explanation the company gave — it represented the “overall value this treatment brings to patients, caregivers and society” — came right out of Mick Kolassa’s playbook.
For many years, Kolassa was the man drug companies turned to when they wanted advice on how to price a drug.
